We are excited to share that Jennifer Che, President and Managing Director of Eagle IP, will be attending the Life Sciences Patents Network (LSPN) North America Spring conference, held from April 29–30, 2026, at the Hyatt Regency Boston.

As a premier gathering for the global biopharma and medtech communities, LSPN Boston provides a vital platform for IP leaders to discuss the strategies and legal frameworks driving innovation in the life sciences. With her extensive background as  a medicinal chemist, US Patent Attorney, and Managing Director of a team of Chinese patent attorneys, Jennifer is uniquely positioned to engage with industry peers on the complex IP challenges, especially with respect to Asia, facing modern biotech companies.

If you are attending LSPN Boston and would like to discuss global IP strategy or specific developments in the Asian markets, Jennifer would welcome the opportunity to connect. Please contact us to schedule a meeting during the conference.

我们的过去活动

Recommended Insights

Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents

2026年4月13日
For many foreign companies interested in the broader Asian market, Hong Kong is a strategically important jurisdiction. However, because of its unique legal framework, domestic and foreign companies alike are confused by how IP protection works in Hong Kong. Missteps in such understanding can lead to critical, costly "gaps" in IP protection. To safeguard innovations […]

Updates on Hong Kong Patents Examination Guidelines in 2024

2024年2月29日
The Intellectual Property Department of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKIPD) has recently made several updates to the Hong Kong Patents Examination Guidelines, effective from 26 January, 2024. These changes mainly clarify and reflect the Registry’s current practices regarding patent examination for Standard Patent (R) […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

Obviousness: can features from different categories of products be combined to invalidate a design patent?

2025年9月18日
Introduction “I have a tank, I have a gun—boom! Tank gun?” Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Over the next several months we will be highlighting many […]
Top crossarrow-right